CELID DNA Production for AAV Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for producing recombinant AAV particles often result in encapsidation of non-vector DNA, leading to immune responses and inefficiencies due to residual plasmid DNA and bacterial methylation patterns, which are detrimental for therapeutic uses.
Innovation Solution
The production of closed-ended, linear, duplex (CELID) DNA molecules flanked by AAV ITRs, lacking Rep and Cap protein sequences, is introduced into mammalian cells to replicate and isolate recombinant AAV particles, minimizing non-vector DNA encapsidation and bacterial contamination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce recombinant AAV particles, then production efficiency is maintained, but non-vector DNA is encapsidated leading to immune responses and reduced purity
Solution Approach 1:
The patent divides the DNA molecule into specific segments: inverted terminal repeats (ITRs) at the ends and heterologous DNA in the middle. This segmentation allows the AAV replication machinery to recognize and process only the intended vector DNA flanked by ITRs, while leaving other DNA segments (like plasmid backbone) outside the encapsidation scope, thereby preventing non-vector DNA packaging and reducing immune responses.
Solution Approach 2:
The patent extracts and eliminates problematic elements from the production system. Specifically, it removes bacterial methylation patterns and plasmid DNA contaminants from the final AAV particle formulation through purified production methods, leaving only the desired recombinant AAV particles with high purity and reduced immunogenicity.
2Ease of manufacture
If plasmid DNA is used for AAV production, then ease of manufacture is improved, but bacterial methylation patterns and plasmid DNA impurities remain
Solution Approach 1:
The patent converts the potential harm of using plasmid DNA (which contains bacterial methylation patterns and impurities) into a benefit by employing a purified production system. The method uses plasmid DNA as a starting material but incorporates purification steps that remove bacterial contaminants and methylation patterns, transforming what would be harmful impurities into a high-purity final product suitable for therapeutic use.
3Productivity
If residual plasmid DNA is present in recombinant AAV particles, then production yield is maintained, but therapeutic efficacy is reduced due to immune responses
Solution Approach 1:
The patent implements a continuous purified production process that maintains high productivity while continuously removing impurities. The method sustains efficient AAV particle production through optimized transfection and replication conditions, while simultaneously applying purification steps that eliminate plasmid DNA and bacterial contaminants, ensuring both high yield and high therapeutic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces immune response triggers and improves the purity of recombinant AAV particles by eliminating prokaryotic DNA impurities, enhancing their therapeutic efficacy and safety.
Implementation Method 1
culturing the cell under conditions suitable for replication of the nucleic acid molecule
Data Source
AI summary
Closed-ended, linear, duplex (CELID) DNA molecules, recombinant AAV (rAAV), particles comprising CELID DNA, methods of making such molecules and particles, and therapeutic applications of such particles.